Related Experiment Video
Updated: Aug 8, 2026

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells
Published on: August 17, 2022
Clinical manifestations of chronic inflammatory demyelinating polyneuropathy with anti-cardiolipin antibodies
1Division of Neurology, First Department of Internal Medicine, Osaka Medical College, Osaka, Japan. in1045@poh.osaka-med.ac.jp
Objective:
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune syndrome where certain autoantibodies define clinicopathologic subgroups. In the present study, serum anti-cardiolipin antibodies (aCL) were evaluated.
Materials And Methods:
We investigated aCL in sera from 21 patients diagnosed with CIDP in our hospital between 1991 and 2001. The four CIDP patients with aCL (aCL+) were compared with 17 patients without aCL (aCL-).
Results:
All aCL+ patients displayed sensory-motor polyneuropathy, with severity and distribution of weakness resembling those in aCL- patients. Anti-nuclear antibody titer of aCL+ patients were significantly higher than those in aCL- patients. None of aCL+ patients presented clinical manifestations of primary anti-phospholipid syndrome (APS), such as thromboses or recurrent abortion. Although the aCL+ patients were older and had more complications and more severe pathologic features than aCL- patients, they responded well to steroid pulse or intravenous immunoglobulin.
Conclusion:
The aCL in CIDP apparently differ from 'autoimmune' aCL in APS, instead being among the autoantibodies pathologically involved in CIDP subgroups.
Related Concept Videos
Endocarditis II: Clinical Features of Infective Endocarditis
Myocarditis I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Cardiomyopathy II: Dilated Cardiomyopathy
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

